Russell Alan J. - 01 May 2023 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role: Chief Scientific Officer, Director
Signature: /s/ John R. Moore, Attorney-in-Fact for Russell Alan J
Issuer symbol: EWTX
Transactions as of: 01 May 2023
Net transactions value: -$14,266
Form type: 4
Filing time: 03 May 2023, 18:26:08 UTC
Previous filing: 10 Aug 2022
Next filing: 18 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EWTX	Common Stock	Options Exercise	$0	+5,208	+3%	$0.000000	177,793	01 May 2023	Direct
transaction	EWTX	Common Stock	Sale	$14,266	-1,602	-0.9%	$8.90	176,191	02 May 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EWTX	Restricted Stock Units	Options Exercise	$0	-5,208	-33%	$0.000000	10,417	01 May 2023	Common Stock	5,208	$0.000000	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.